Inhibitors of RTP801 and their use in disease treatment

Details Inhibitors of RTP801 and their use in disease treatment Inhibitors of RTP801 and their use in disease treatment

2011-01-18

2011-01-18

Bowman, Amy (Department: 1635)

Organic compounds -- part of the class 532-570 series

Organic compounds

Carbohydrates or derivatives

C536S023100, C514S04400A

Reexamination Certificate

active

07872119

ABSTRACT:
The present invention provides novel molecules, compositions, methods and uses for treating microvascular disorders, eye diseases respiratory conditions and hearing disorders based upon inhibition of the RTP801 gene and/or protein.

REFERENCES:
patent: 5898031 (1999-04-01), Crooke
patent: 6107094 (2000-08-01), Crooke
patent: 6372249 (2002-04-01), Smith et al.
patent: 6455674 (2002-09-01), Einat et al.
patent: 7452987 (2008-11-01), Giese et al.
patent: 7626015 (2009-12-01), Feinstein et al.
patent: 7655788 (2010-02-01), Khvorova et al.
patent: 2002/0119463 (2002-08-01), Faris et al.
patent: 2002/0137077 (2002-09-01), Hopkins et al.
patent: 2003/0104973 (2003-06-01), Einat et al.
patent: 2003/0108871 (2003-06-01), Kaser
patent: 2003/0165864 (2003-09-01), Lasek et al.
patent: 2003/0207840 (2003-11-01), Riggins et al.
patent: 2005/0080246 (2005-04-01), Allerson et al.
patent: 2006/0217329 (2006-09-01), Feinstein
patent: 2007/0281326 (2007-12-01), Wechsler et al.
patent: 2008/0064650 (2008-03-01), Feinstein et al.
patent: 2008/0188647 (2008-08-01), Khvorova
patent: 19816395 (1999-10-01), None
patent: 1 394 274 (2004-03-01), None
patent: 1009753 (2005-04-01), None
patent: 2003-259877 (2003-09-01), None
patent: WO 99/09046 (1999-02-01), None
patent: WO 00/14283 (2000-03-01), None
patent: WO 00/44895 (2000-08-01), None
patent: WO 00/61620 (2000-10-01), None
patent: WO 00/77022 (2000-12-01), None
patent: WO 01/12659 (2001-02-01), None
patent: WO 01/36646 (2001-05-01), None
patent: WO 01/70979 (2001-09-01), None
patent: WO 01/75164 (2001-10-01), None
patent: WO 01/77289 (2001-10-01), None
patent: WO 02/31111 (2002-04-01), None
patent: WO 02/44321 (2002-06-01), None
patent: WO 02/46465 (2002-06-01), None
patent: WO 02/055693 (2002-07-01), None
patent: WO 02/101075 (2002-12-01), None
patent: WO 03/010205 (2003-02-01), None
patent: WO 03/070918 (2003-08-01), None
patent: WO 03/074654 (2003-09-01), None
patent: WO 03/101283 (2003-12-01), None
patent: WO 2004/015107 (2004-02-01), None
patent: WO 2004/018999 (2004-03-01), None
patent: WO 2004/030615 (2004-04-01), None
patent: WO 2004/035615 (2004-04-01), None
patent: WO 2004/039956 (2004-05-01), None
patent: WO 2004/042024 (2004-05-01), None
patent: WO 2004/042024 (2004-05-01), None
patent: WO 2004/045543 (2004-06-01), None
patent: WO 2004/045543 (2004-06-01), None
patent: WO 2004/045545 (2004-06-01), None
patent: WO 2004/060270 (2004-07-01), None
patent: WO 2004/076633 (2004-09-01), None
patent: WO 2004/091383 (2004-10-01), None
patent: WO 2005/016000 (2005-02-01), None
patent: WO 2008/106102 (2008-09-01), None
patent: WO 2009/116037 (2009-09-01), None
Scherer et al., Approaches for the sequence-specific knockdown of mRNA, 2003, Nat. Biotechnol., 21(12), pp. 1457-1465.
Mahato et al., Modulation of gene expression by antisense and antigene oligodeoxynucleotides and small interfering RNA, Jan. 2005, Expert Opinion on Drug Delivery, vol. 2, No. 1, pp. 3-28.
Zhang et al., Targeted Gene Silencing by Small Interfering RNA-Based Knock-Down Technology, 2004, Current Pharmaceutical Biotechnology, vol. 5, p. 1-7.
Amarzguioui M, Holen T, Babaie E, Prydz H. (2003) Tolerance for mutations and chemical modifications in a siRNA. Nucleic Acids Res. 31(2) :589-95.
Barik, Sailen (2005). “Silence of the Transcripts; RNA Interference In Medicine,”J. Mol. Med. 83:764-773.
Bartel, David P. et al. (2004). “MicroRNAs: Genomics Biogenesis, Mechanism, and Function,”Cell, 116:281-297.
Bernstein Emily et al. (2001). “Role for a Bidentate Ribonuclease in the Initiation Step of RNA Interference,”Nature, 409:363-366.
Bitko, Vira et al. (2004). “Inhibition of Respiratory Viruses by Nasally Administered siRNA,”Nature Medicine, 11(1):50-55.
Brafman, A. et al., (2004) “Inhibition of Oxygen-Induced Retinopathy in RTP801-Deficient Mice,”Investigative Ophthalmology & Visual Science, 45(10): 3796-3805.
Braasch Da, et al. (2003) “RNA interference in mammalian cells by chemically-modified RNA,”Biochemistry, 42:7967-7975.
Brugarolas, J. et al., (2004) “Regulation of mTOR Function in Response to Hypoxia by REDD1 and the TSC1/TSC2 Tumor Suppressor Complex,”Genes & Development, 18: 2893-2904.
Brummelkamp, Thijn R. et al. (2002). “A System for Stable Expression of Short Interfering RNAs in Mammalian Cells,”Science, 296: 550-553.
Caplen, Natasha J. et al. (2001). “Specific Inhibition of Gene Expression by Small Double-Stranded RNAs in Invertebrate Vertebrate Systems,”PNAS, 98(17):9742-9747.
Chakraborty, Chiranjib (2007) “Potentiality of Small Interfering RNAs (siRNA) as Recent Therapeutic Targets for Gene-Silencing,”Current Drug Targets, 8:469-482.
Chalk, Alistair M. et al., (2004). “Improved and Automated Prediction of Effective siRNA,”Biochemical and Biophysical Research Communications, 319:264-274.
Czauderna F, Fechtner M, Dames S, Aygün H, Klippel A, Pronk GJ, Giese K, Kaufmann J. (2003) “Structural variations and stabilising modifications of synthetic siRNAs in mammalian cells,”Nucleic Acids Res. 31(11):2705-16.
Elbashir, Sayda M. et al. (2000). “RNA Interference is Mediated by 21- and 22-nucleotide RNAs,”Genes & Development, 15:188-200.
Elbashir, Sayda M. et al. (2001). “Duplexes of 21-nucleotide RNAs mediated RNA interference in cultured mammalian cells,”Nature, 411:494-498.
Elbashir SM, Martinez J, Patkaniowska A, Lendeckel W, Tuschl T. (2001) “Functional anatomy of siRNAs for mediating efficient RNAi in Drosophila melanogaster embryo lysate,”EMBO J. 20(23):6877-88.
Fire, Andrew et al., (1998). “Potent and Specific Genetic Interference by Double-stranded RNA in Caenorhabditis Elegans,”Nature, 391:806-811.
Ellisen, L. et al., (2002) “REDD1, A Developmentally Regulated Transcriptional Target of p63 and p53, Links p63 to Regulation of Reactive Oxygen Species,”Molecular Cell, 10:995-1005.
Frolov, A. et al., (2003) “Response Markers and the Molecular Mechanisms of Action of Gleevec in Gastrointestinal Stromal Tumors,”Molecular Cancer Therapeutics, 2: 699-709.
Kim, J. et al., (2003) “Identification of Amyloid β-peptide Responsive Genes by cDNA Microarray Technology: Involvement ofRTP801in Amyloid β-peptide Toxicity,”Experimental and Molecular Medicine, 35(5): 403-411.
Lal, A. et al., (2001) “Transcriptional Response to Hypoxia in Human Tumors,”Journal of the National Cancer Institute, 93(17): 1337-1343.
Lee, Youngtae et al., (2003). “The nuclear RNase III Drosha initiates microRNA processing,” Nature, 425:415-419.
Lee, M. et al., (2004) “Sp1-Dependant Regulation of the RTP801 Promoter and Its Application to Hypoxia-Inducible VEGF Plasmid for Ischemic Disease,”Pharmaceutical Research, 21(5): 736-741.
Levenkova, Natasha et al., (2004). “Gene specific siRNA selector,”Bioinformatics, 20(3)430-432.
Lewis MI, et al. (2002) Apoptosis as a potential mechanism of muscle cachexia in chronic obstructive pulmonary disease.Am. J. Respir. Crit. Care Med. 166:434-435.
McManus, Michael T. and Sharp, Phillip A., (2002). “Gene Silencing in Mammals by Small Interfering RNAs,” Genetics, 3:737-747.
Prakash TP, Allerson CR, Dande P, Vickers TA, Sioufi N, Jarres R, Baker BF, Swayze EE, Griffey RH, Bhat B. (2005) “Positional effect of chemical modifications on short interference RNA activity in mammalian cells,”J Med Chem. 48(13):4247-53.
Rangasamy, R. et al., (2004) “Genetic Ablation of Nrf2 Enhances Susceptibility to Cigarette Smoke-Induced Emphysema in Mice,”The Journal of Clinical Investigation, 114(9): 1248-1259.
Reich, S. et al., (2003). “Small interfering RNA (siRNA) targeting VEGF effectively inhibits ocular neovascularization in a mouse model,”Molecular Vision, 9:210-216.
Reiling, J. and Hafen, E., (2004) “The Hypoxia-Induced Paralogs Scylla and Charybdis Inhibit Growth by Down-Regulating S6

Affiliated with

Also associated with

Rating

Inhibitors of RTP801 and their use in disease treatment does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Inhibitors of RTP801 and their use in disease treatment, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibitors of RTP801 and their use in disease treatment will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2629951